METAVIA INC (MTVA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.75-4.89%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · MTVA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
MTVA — earnings miss
Dated 2026-08-06
and Item 7.01, respectively, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. The Company’s submission of this Report shall not be deemed an admission as to th…
Why it matters: Updates on cash position will show if the company can fund operations through 2026.
Supportive ifCash and cash equivalents remain above $12.6 million.
Worry ifCash and cash equivalents drop below $12.6 million.
Why it matters: R&D costs are going up. This may make it hard to manage costs while developing drugs.
Worry ifR&D expenses increase more than 10% from the previous quarter.
Less concerning ifR&D costs stay the same or go down from last quarter.
Why it matters: Earnings results will show how well the company is doing. This can affect investor confidence.
Watch forEarnings show more revenue and fewer operating losses than before.
Also watch forEarnings show continued losses and no revenue growth compared to previous quarters.
Why it matters: Updates on cash will show if the company can pay for its work. This is important for projects.
Watch forCash and cash equivalents increase to over $15 million after debt issuance.
Also watch forCash goes down or stays under $12 million.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$274 on $10,000 · ±2.7% | How much price usually moves either way. |
| Bad day | $1,430 loss on $10,000 · 14.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,412 loss on $10,000 · 94.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Results will show if DA-1726 can maintain weight loss and improve liver health. This data is crucial for its future development.
Supportive ifData from the Phase 1 Part 3 trial shows weight loss of at least 9.1% and improved liver metrics.
Worry ifResults show no big weight loss or liver improvements compared to placebo.
Why it matters: New data could strengthen DA-1726's profile and attract investor interest. This is important for its market perception.
Supportive ifNew data shows ongoing weight loss and better liver health.
Worry ifData shows no big changes or bad results.
Why it matters: Increasing losses would show that the company is struggling to control costs. This could raise concerns about its path to profitability.
Worry ifQ2 operating losses were worse than -$4.0 million.
Less concerning ifQ2 operating losses improve to better than -$4.0 million.
Why it matters: Topline data will show if DA-1726 can maintain weight loss effects. This is key for its future in obesity treatment.
Supportive ifTopline data shows at least 9% mean weight loss sustained beyond Day 54 in the Phase 1 study.
Worry ifTopline data shows less than 9% mean weight loss or evidence of plateau.
Why it matters: A meeting at the end of Phase 2 could clarify how vanoglipel will develop for MASH and diabetes.
Supportive ifThe meeting date with the FDA will be announced. It will discuss vanoglipel's development path.
Worry ifNo announcement of the meeting by the end of 2026.
Why it matters: Having enough cash is important. It helps fund clinical trials and keep operations running.
Worry ifCash and cash equivalents remain above $10 million through Q4 2026.
Less concerning ifCash and cash equivalents drop below $10 million before the end of 2026.